AZN - Mineralys: 2nd Half 2024 Hypertension Data Readout

2024-02-09 09:33:11 ET

Summary

• Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN.
• Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024.
• Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025.
• The global hypertension market is expected to reach $43.18 billion by 2030.

Mineralys Therapeutics, Inc. ( MLYS ) has made significant progress for its pipeline, because it has been able to launch two phase 3 studies, which are using lorundrostat for the treatment of patients with uncontrolled and resistant hypertension. One of these two late-stage studies, known as ADVANCE-HTN, is expected to have a data readout in the 2nd half of 2024. However, the second late-stage study for this particular program is not expected to have a data release until the 2nd half of 2025....

For further details see: